The Colen Lab performs
Imaging Genomics in Cancer
We are considered one of the early pioneers and developers of the field of quantitative imaging genomics in cancer. We were the first to publish on quantitative imaging genomics in glioblastoma. In this paper, we found that patients with GBM who have high FLAIR peritumoral volume (reflecting high edema/invasion) have differential genomic expression profiles, with the top gene hit being Periostin (POSTN). In these patients, POSTN was associated with an invasive profile in GBM and poor survival, a unique finding not previously described. Since then, we have published multiple papers on imaging genomics in brain tumors. Our papers have been well cited; and since our initial publication, multiple papers on imaging genomics have surfaced. Due to this, the imaging landscape of cancer, specifically GBM, has changed and enhanced the use of imaging in the context of genomic profiles and tumor heterogeneity.
We are considered one of the early pioneers and developers in the field of
Imaging in Immunotherapy
Our lab has recently begun to focus on
Co-Clinical Trials Using Imaging and Imaging Genomics
Our lab is the first to perform preclinical and co-clinical validation of imaging genomics using both in-vitro and in-vivo mechanistic experimental models. Here, we also demonstrate that
Big Data in Imaging and Imaging –omics
Our lab is considered one of the developers of imaging big data where we merge imaging and other –omic data into large centralized databases and perform large-scale imaging genomic analysis. In our lab, we developed software code and scripts that are used for performing these correlations and adaptive/predictive modeling. With this, we work bidirectional imaging –omics in order to determine with higher accuracy response to treatment and patient outcomes.